Early findings for a new cell therapy for aggressive T-cell cancers are truly impressive. In an initial study of 11 patients, 72.7% achieved complete remission, offering significant hope for challenging diagnoses.
Innovative CAR-T cell therapy receives FDA breakthrough therapy designationResearchers at Washington University School of Medicine in St. Louis have developed WU-CART-007, an "off-the-shelf" CAR-T cell immunotherapy for rare and aggressive T-cell acute lymphoblastic leukemiamedicine.wustl.edu